3,4-Diaminopyridine in Childhood Myasthenia: Double-Blind, Placebo-Controlled Trial
Authors:
- 1 November 1996
- journal article
- clinical trial
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 11 (6) , 458-461
Abstract
Eleven patients with congenital and five with juvenile myasthenia gravis, aged 5 to 24 years, were given 3,4-diaminopyridine in a double-blind, placebo-controlled, crossover study. Clinical improvement was observed in 5 of 11 congenital myasthenia patients, and placebo effect, in 3 of 11. Juvenile myasthenia patients did not respond. Single-fiber electromyographic studies did not reveal any changes correlating with the clinical status of the patient. This study demonstrates the importance of double-blind and placebo-controlled studies to determine the effect of 3,4-diaminopyridine in congenital myasthenia. This drug may have different effects on various presynaptic and postsynaptic defects of neuromuscular transmission resulting in congenital myasthenia syndromes. (J Child Neurol 1996;11:458-461).Keywords
This publication has 6 references indexed in Scilit:
- Newly recognized congenital myasthenic syndrome associated with high conductance and fast closure of the acetylcholine receptor channelAnnals of Neurology, 1993
- 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Preliminary trial of 3,4‐diaminopyridine in patients with multiple sclerosisAnnals of Neurology, 1990
- 3,4-Diaminopyridine in the Treatment of Lambert–Eaton Myasthenic SyndromeNew England Journal of Medicine, 1989
- Axonal stimulation for end-plate jitter studies.Journal of Neurology, Neurosurgery & Psychiatry, 1986
- A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine‐induced ion channelAnnals of Neurology, 1982